Advertisement

Cellular and molecular mechanism of arsenic trioxide in the treatment of hematopoietic malignancies

  • Guoqiang Chen
  • Xun Cai
  • Yulei Shen
  • Li Zhou
  • Qi Zhu
  • Yun Yu
  • Peimin Jia
  • Xinhua Zhu
  • Saijuan Chen
  • Zhenyi Wang
  • Zhu Chen
Feature Article
  • 25 Downloads

Keywords

Arsenic Chronic Myeloid Leukemia Arsenite Acute Promyelocytic Leukemia Arsenic Trioxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Culter EG, Bradford EH. Action of iron, cod-liver oil and arsenic on the globular richness of the blood. Am J Med Sci 1878; 75: 74.CrossRefGoogle Scholar
  2. 2.
    Forkner CE and Scott TFM. Arsenic as a therapeutic agent in CML. JAMA 1931; 97: 3.Google Scholar
  3. 3.
    Stephens DJ and Lawrence JS. The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia. Ann Inatern Med 1936; 9: 1488.Google Scholar
  4. 4.
    Kwong YL, Todd D. Delicious poison: arsenic for the treatment of leukemia Blood 1997; 89: 3487.Google Scholar
  5. 5.
    Mervis J. Ancient remedy performs new tricks. Science 1996; 273(5275): 578.PubMedCrossRefGoogle Scholar
  6. 6.
    32 1992; 12 (3): 170.Google Scholar
  7. 7.
    72 1996; 17(1): 58.Google Scholar
  8. 8.
    Shen ZX, Chen GQ, Ni JH, et al. Use of As2O3 in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354.PubMedGoogle Scholar
  9. 9.
    Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen GQ, Shi XG, Tang W, et al. Use of As2O3 in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89(9): 3345–3353.PubMedGoogle Scholar
  11. 11.
    Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of As2O3 in the treatment of APL: As2O3 induces NB4 cell apoptosis with down-regulation of bcl-2 expression and alteration of PML-RARα/PML protein localization. Blood 1996; 88: 1052.PubMedGoogle Scholar
  12. 12.
    Kitamura K, Yoshida H, Ohno R, et al. Toxic effects of arsenic and other metal ions on APL cells. International J Hematol 1997; 65: 179.CrossRefGoogle Scholar
  13. 13.
    Kitamura K, Kiyoi H, Yoshida H, et al. New retinoids and arsenic for the treatment of refractory APL: Clinical and basic studies for the next generation. Cancer Chemother Pharmacol 1997; 40: 536.CrossRefGoogle Scholar
  14. 14.
    Ochi T, Nakajima F, Sakurai T, et al. Dimethylarsenic acid causes apoptosis in HL-60 cells via interaction with glutathione. Arch Toxicol 1996; 70(12): 815–821.PubMedCrossRefGoogle Scholar
  15. 15.
    Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90(2): 124–133.PubMedCrossRefGoogle Scholar
  16. 16.
    Wang ZG, Rivi R, Delva L, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood 1998; 92(5): 1497–1504.PubMedGoogle Scholar
  17. 17.
    Konig A, Wrazel L, Warrell Jr RP, et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997; 90: 562–570.PubMedGoogle Scholar
  18. 18.
    Zhu XH, Shen YL, Jing YK, et al. Arsenic trioxide (As2O3) induces malignant lymphocyte growth inhibition and apoptosis at clinically achievable concentrations. J Natl Cancer Inst 1999; in press.Google Scholar
  19. 19.
    Akao Y, Mizoguchi H, Kojima S, et al. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and down-regulation of bcl-2 protein. Br J Haematol 1998; 102: 1055–1060.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhang W, Ohnishi K, Shigeno K, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12: 1383–1391.PubMedCrossRefGoogle Scholar
  21. 21.
    Ishitsuka K, Hanada S, Utsunomiya A, et al. Arsenic trioxide inhibits growth of human T-cell leukemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998; 103: 721–728.PubMedCrossRefGoogle Scholar
  22. 22.
    Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic and INF synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus-transformed cells. Blood 1999; 93: 278–283.PubMedGoogle Scholar
  23. 23.
    Cai X, Shen YL, Chen GQ, et al. As2O3-induced APL cell apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse/cas- pase activation and retinoic acid signaling, in preparationGoogle Scholar
  24. 24.
    Yager JW, Wiencke JK, Inhibition of PARP by arsenite. Mutat Res 1997; 386: 345–351.PubMedCrossRefGoogle Scholar
  25. 25.
    Lynn S, Shiung JN, Gurr JR, et al. Arsenite stimulates poly(ADP-ribosylation) by generation of nitric oxide. Free Radic Biol Med 1998; 24: 442–449.PubMedCrossRefGoogle Scholar
  26. 26.
    Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999; 59(4): 776–780.PubMedGoogle Scholar
  27. 27.
    Wang TS, Kuo CF, Jan KY, et al. Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J Cell Physiol 1996; 169(2): 256–268.PubMedCrossRefGoogle Scholar
  28. 28.
    Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998; 177(2): 324–333.PubMedCrossRefGoogle Scholar
  29. 29.
    Dai J, Weinberg RS, Waxman S, et al. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic through modulation of the glutathione. Blood 1999; 93(1): 268.PubMedGoogle Scholar
  30. 30.
    Zhu J, Koken MH, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of APL. Proc Natl Acad Sci USA 1997; 94: 3978–3983.PubMedCrossRefGoogle Scholar
  31. 31.
    Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998; 17: 61–70.PubMedCrossRefGoogle Scholar
  32. 32.
    Andre C, Guillemin MC, Zhu J, et al. The PML and PML/RARα domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. Exp Cell Res 1996; 229: 253–260.PubMedCrossRefGoogle Scholar
  33. 33.
    Look AT, Arsenic and apoptosis in the treatment of APL. J Natl Cancer Inst 1998; 21(90): 86–88.CrossRefGoogle Scholar
  34. 34.
    Koken MH, Daniel MT, Gianni M, et al. Retinoic acid, but not arsenic, degrades the PLZF/RARα without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t (11; 17) (q23; q21) APL patient. Oncogene 1999; 18(4): 1113–1118.PubMedCrossRefGoogle Scholar
  35. 35.
    Gianni M, Koken MHM, Chelbi-Alix MK, et al. Combined arsenic and RA treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998; 91: 4300–4304.PubMedGoogle Scholar

Copyright information

© The Chinese Journal of Integrated Traditional and Western Medicine Press 1999

Authors and Affiliations

  • Guoqiang Chen
    • 1
  • Xun Cai
    • 1
  • Yulei Shen
    • 1
  • Li Zhou
    • 1
  • Qi Zhu
    • 1
  • Yun Yu
    • 1
  • Peimin Jia
    • 1
  • Xinhua Zhu
    • 1
  • Saijuan Chen
    • 1
  • Zhenyi Wang
    • 1
  • Zhu Chen
    • 1
  1. 1.Shanghai Institute of Hematology, Ruijin HospitalShanghai Second Medical UniversityShanghai

Personalised recommendations